Elizabeth A M Feijen1, Wendy M Leisenring2, Kayla L Stratton2, Kirsten K Ness2, Helena J H van der Pal2, Huib N Caron2, Gregory T Armstrong2, Daniel M Green2, Melissa M Hudson2, Kevin C Oeffinger2, Leslie L Robison2, Marilyn Stovall2, Leontien C M Kremer2, Eric J Chow2. 1. Elizabeth A.M. Feijen, Helena J.H. van der Pal, Huib N. Caron, and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands; Wendy M. Leisenring, Kayla L. Stratton, and Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Kirsten K. Ness, Gregory T. Armstrong, Daniel M. Green, Melissa M. Hudson, and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center, New York, NY; and Marilyn Stovall, University of Texas MD Anderson Cancer Center, Houston, TX. e.a.feijen@amc.uva.nl. 2. Elizabeth A.M. Feijen, Helena J.H. van der Pal, Huib N. Caron, and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands; Wendy M. Leisenring, Kayla L. Stratton, and Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Kirsten K. Ness, Gregory T. Armstrong, Daniel M. Green, Melissa M. Hudson, and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center, New York, NY; and Marilyn Stovall, University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
PURPOSE: Cumulative anthracycline dose is one of the strongest predictors of heart failure (HF) after cancer treatment. However, the differential risk for cardiotoxicity between daunorubicin and doxorubicin has not been rigorously evaluated among survivors of childhood cancer. These risks, which are based on hematologic toxicity, are currently assumed to be approximately equivalent. PATIENTS AND METHODS: Data from 15,815 survivors of childhood cancer who survived at least 5 years were used. Survivors were from the Emma Children's Hospital/Academic Medical Center (n = 1,349), the National Wilms Tumor Study (n = 364), the St Jude Lifetime Cohort Study (n = 1,695), and the Childhood Cancer Survivor Study (n = 12,407). The hazard ratio (HR) for clinical HF through age 40 years for doses of daunorubicin and doxorubicin (per 100-mg/m(2) increments) was estimated by using Cox regression adjusted for sex, age at diagnosis, treatment with other anthracycline agents and chest radiation, and cohort membership. RESULTS: In total, 5,144 (32.5%) patients received doxorubicin as part of their cancer treatment, whereas 2,243 (14.7%) received daunorubicin. On the basis of 271 occurrences of HF during a median follow-up time after cohort entry of 17.3 years (range, 0.0 to 35.0 years), the cumulative incidence of HF at age 40 years was 3.2% (95% CI, 2.8% to 3.7%). The average ratio of HRs for daunorubicin to doxorubicin was 0.45 (95% CI, 0.23 to 0.73). A similar ratio was obtained by using a linear dose-response model, which yielded an HR of 0.49 (95% CI, 0.28 to 0.70). CONCLUSION: Compared with doxorubicin, daunorubicin was less cardiotoxic among survivors of childhood cancer than most current guidelines suggest. This may have implications for follow-up guidelines. The feasibility of substitution of doxorubicin with daunorubicin in childhood cancer treatment protocols to reduce cardiotoxicity should be additionally investigated.
PURPOSE: Cumulative anthracycline dose is one of the strongest predictors of heart failure (HF) after cancer treatment. However, the differential risk for cardiotoxicity between daunorubicin and doxorubicin has not been rigorously evaluated among survivors of childhood cancer. These risks, which are based on hematologic toxicity, are currently assumed to be approximately equivalent. PATIENTS AND METHODS: Data from 15,815 survivors of childhood cancer who survived at least 5 years were used. Survivors were from the Emma Children's Hospital/Academic Medical Center (n = 1,349), the National Wilms Tumor Study (n = 364), the St Jude Lifetime Cohort Study (n = 1,695), and the Childhood Cancer Survivor Study (n = 12,407). The hazard ratio (HR) for clinical HF through age 40 years for doses of daunorubicin and doxorubicin (per 100-mg/m(2) increments) was estimated by using Cox regression adjusted for sex, age at diagnosis, treatment with other anthracycline agents and chest radiation, and cohort membership. RESULTS: In total, 5,144 (32.5%) patients received doxorubicin as part of their cancer treatment, whereas 2,243 (14.7%) received daunorubicin. On the basis of 271 occurrences of HF during a median follow-up time after cohort entry of 17.3 years (range, 0.0 to 35.0 years), the cumulative incidence of HF at age 40 years was 3.2% (95% CI, 2.8% to 3.7%). The average ratio of HRs for daunorubicin to doxorubicin was 0.45 (95% CI, 0.23 to 0.73). A similar ratio was obtained by using a linear dose-response model, which yielded an HR of 0.49 (95% CI, 0.28 to 0.70). CONCLUSION: Compared with doxorubicin, daunorubicin was less cardiotoxic among survivors of childhood cancer than most current guidelines suggest. This may have implications for follow-up guidelines. The feasibility of substitution of doxorubicin with daunorubicin in childhood cancer treatment protocols to reduce cardiotoxicity should be additionally investigated.
Authors: J D Buckley; B C Lampkin; M E Nesbit; I D Bernstein; S A Feig; J H Kersey; S Piomelli; T Kim; G D Hammond Journal: Med Pediatr Oncol Date: 1989
Authors: M Schrappe; A Reiter; M Zimmermann; J Harbott; W D Ludwig; G Henze; H Gadner; E Odenwald; H Riehm Journal: Leukemia Date: 2000-12 Impact factor: 11.528
Authors: D M Green; Y A Grigoriev; B Nan; J R Takashima; P A Norkool; G J D'Angio; N E Breslow Journal: J Clin Oncol Date: 2001-04-01 Impact factor: 44.544
Authors: J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland Journal: Blood Date: 1982-08 Impact factor: 22.113
Authors: D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia Journal: Ann Intern Med Date: 1979-11 Impact factor: 25.391
Authors: Brent R Weil; Arin L Madenci; Qi Liu; Rebecca M Howell; Todd M Gibson; Yutaka Yasui; Joseph P Neglia; Wendy M Leisenring; Susan A Smith; Emily S Tonorezos; Danielle N Friedman; Louis S Constine; Christopher L Tinkle; Lisa R Diller; Gregory T Armstrong; Kevin C Oeffinger; Christopher B Weldon Journal: J Clin Oncol Date: 2018-04-17 Impact factor: 44.544
Authors: Stephanie B Dixon; Eric J Chow; Lars Hjorth; Melissa M Hudson; Leontien C M Kremer; Lindsay M Morton; Paul C Nathan; Kirsten K Ness; Kevin C Oeffinger; Gregory T Armstrong Journal: Pediatr Clin North Am Date: 2020-12 Impact factor: 3.278
Authors: James E Bates; Rebecca M Howell; Qi Liu; Yutaka Yasui; Daniel A Mulrooney; Sughosh Dhakal; Susan A Smith; Wendy M Leisenring; Daniel J Indelicato; Todd M Gibson; Gregory T Armstrong; Kevin C Oeffinger; Louis S Constine Journal: J Clin Oncol Date: 2019-03-12 Impact factor: 44.544
Authors: Eugene Suh; Kayla L Stratton; Wendy M Leisenring; Paul C Nathan; Jennifer S Ford; David R Freyer; Jennifer L McNeer; Wendy Stock; Marilyn Stovall; Kevin R Krull; Charles A Sklar; Joseph P Neglia; Gregory T Armstrong; Kevin C Oeffinger; Leslie L Robison; Tara O Henderson Journal: Lancet Oncol Date: 2020-02-14 Impact factor: 41.316
Authors: Yasmin Hamirani; Ibrahim Fanous; Christopher M Kramer; Andrew Wong; Michael Salerno; Patrick Dillon Journal: Med Oncol Date: 2016-06-22 Impact factor: 3.064
Authors: Hannah E Williams; Carrie R Howell; Wassim Chemaitilly; Carmen L Wilson; Seth E Karol; Vikki G Nolan; Matthew P Smeltzer; Daniel M Green; Matthew J Ehrhardt; Daniel A Mulrooney; Ching-Hon Pui; Melissa M Hudson; Leslie L Robison; Kirsten K Ness Journal: Cancer Date: 2019-11-12 Impact factor: 6.860
Authors: Wadi Mawad; Luc Mertens; Joseph J Pagano; Eugenie Riesenkampff; Marjolein J E Reichert; Seema Mital; Paul F Kantor; Mark Greenberg; Peter Liu; Paul C Nathan; Lars Grosse-Wortmann Journal: Eur Heart J Cardiovasc Imaging Date: 2021-03-22 Impact factor: 6.875